News for Molecular Partners AG (MOLN.SW)

On September 30, 2024, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (Trades, Portfolio), executed a noteworthy transaction by acquiring

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic part

**media[652295]**

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadershi

Michael Vasconcelles, M.D., joins Day One Biopharmaceuticals (DAWN) as Head of Research & Development. Dr. Vasconcelles brings over 25 years of experien

Molecular Partners plans to streamline operations, potentially reducing its workforce by 24% to extend cash longevity until 2028. The average analyst pr

Molecular Partners AG (NASDAQ: MOLN) to participate in two key investor conferences in May 2025. Events include H.C. Wainwright 3rd Annual BioConnect an

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; MOLN), a clinical-stage biotech company

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well

Molecular Partners (MOLN) has announced the presentation of significant preclinical findings at the American Association for Cancer Research annual meeting 2025

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readou

\n Molecular Partners (MOLN) shareholders approved all board proposals at the Annual General Meeting. The company reported a net loss of CHF 50.6 million f

**media[597168]**

After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Revenue: CHF5 million in 2024, exclusively from the Novartis collaboration.Operating Expenses: CHF66 million, within the guidance range of CHF65 million to CHF

Mar 07, 2025 / 01:00PM GMTOperator Good morning, and welcome to the Molecular Partners fourth quarter and full year 2024 results call. (Operator Instructions).

Molecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ETCompany ParticipantsMichael Tobias Stumpp - EVP ProjectsPatrick...

**media[559663]**